NCT00288522View on ClinicalTrials.gov

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Thyroid-Associated Ophthalmopathy

Interventions

DRUG

Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days

Trial Locations (1)

03012

Hospital General d'Alacant, Alicante

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Ipsen

INDUSTRY